Loading...

Purified anti-human CD3 Antibody

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_Purified_053107
Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
  • OKT3_Purified_053107
    Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
317301 25 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317302 100 µg 44€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  2. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
  3. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
  4. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  5. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  6. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  7. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  8. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  9. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
  10. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
  11. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
  12. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  13. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  14. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  15. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  16. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  17. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  18. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
  19. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  20. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  21. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  22. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
  23. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
  24. Willimsky G, et al. 2021. Elife. 10:. PubMed
  25. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  26. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  27. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
  28. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  29. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  30. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  31. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  32. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
  33. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  34. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
  35. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  36. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  37. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  38. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  39. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  40. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
  41. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
  42. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  43. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  44. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
  45. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
  46. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
  47. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  48. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  49. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
  50. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  51. Alter G, et al. 2008. J Virol. 82:9668. PubMed
  52. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  53. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  54. Zuñiga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
  55. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
  56. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
  57. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  58. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  59. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  60. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  61. Pinto J, et al. 2010. Immunology. 130:217. PubMed
  62. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  63. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
  64. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  65. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
  66. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  67. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  68. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
  69. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
  70. Ardain A, et al. 2019. Nature. 570:528. PubMed
  71. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  72. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  73. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  74. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
  75. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  76. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  77. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
  78. Henrick BM, et al. 2021. Cell. . PubMed
  79. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  80. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  81. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
  82. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  83. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
  84. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
  85. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  86. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
  87. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
  88. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  89. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  90. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
  91. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
  92. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
  93. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
  94. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  95. Naranbhai V, et al. 2022. Cell. . PubMed
  96. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  97. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
  98. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  99. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  100. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  101. He Y, et al. 2021. eLife. 10:00. PubMed
  102. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
  103. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
  104. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  105. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  106. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
  107. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  108. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed
  109. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
RRID
AB_571926 (BioLegend Cat. No. 317301)
AB_571927 (BioLegend Cat. No. 317302)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org
Go To Top Version: 2    Revision Date: 06-12-2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account